Xenon Pharmaceuticals (XENE) reported a Q1 net loss late Monday of $0.83 per diluted share, widening from a loss of $0.62 a year earlier.
Analysts polled by FactSet expected a loss of $0.91.
Revenue for the three months ended March 31 was $7.5 million, compared with nil a year earlier. Analysts expected $2.2 million.
Based on current operating plans, Xenon said it anticipates having sufficient cash to fund operations into 2027.
Shares of the company were down more than 13% in recent after-hours activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。